RxDoctor Payments Data

Disha Shah, MD

Clinical Neurophysiology · Louisville, KYNPI 1366671265

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $101,315 of the $122,083 with a category attached, or 83.0%. AbbVie accounts for 86.1% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $41,957 and has fallen 90.6% since, to $3,929 in 2025.

$122,083in general payments, 2019–2025

Across 1,013 payments — averaging $120.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$105K
  • EMD Serono, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Vanda Pharmaceuticals Inc.$1K
  • UCB, Inc.$759
  • Livanova USA, Inc.$691
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$2,4002%
  • Speaking & faculty fees$101,31583%
  • Travel & lodging$1,2541%
  • Food & beverage$16,71014%
  • Education$4040%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)264$105,064
EMD Serono, Inc.23$2,825
Teva Pharmaceuticals USA, Inc.47$1,185
Vanda Pharmaceuticals Inc.20$1,007
UCB, Inc.32$759
Livanova USA, Inc.10$691
Biogen33$665
Lilly USA, LLC30$608
Novartis39$599
Pfizer59$580
Sunovion Pharmaceuticals Inc.43$563
AstraZeneca(2 entities)26$538
Biohaven Pharmaceuticals, Inc.32$433
Bristol Myers Squibb25$383
CSL Behring17$319
Biohaven Pharmaceutical Holding Company Ltd.32$269
Argenx US, Inc.13$261
Genentech USA, Inc.13$255
Acadia Pharmaceuticals Inc8$254
Upsher-smith Laboratories LLC12$237
Grifols USA, LLC11$228
Lundbeck LLC10$225
Amgen(2 entities)11$221
Eisai Inc.12$207
Supernus Pharmaceuticals, Inc.22$193
Catalyst Pharmaceuticals, Inc.10$192
Johnson & Johnson(2 entities)10$192
TG Therapeutics, Inc.11$189
SK Life Science, Inc.7$187
Merz Pharmaceuticals, LLC8$184
Neurelis, Inc.8$169
Medtronic2$164
Ipsen Biopharmaceuticals, Inc6$134
Takeda Pharmaceuticals U.S.A., Inc.5$121
Scilex Pharmaceuticals Inc.6$120
Boston Scientific6$116
E.r. Squibb & Sons, L.L.C.1$113
Arbor Pharmaceuticals, Inc.6$109
Endo Pharmaceuticals Inc.5$102
Otsuka America Pharmaceutical, Inc.5$98
Zyla Life Sciences, Inc.6$97
Myriad Genetic Laboratories, Inc.5$96
MDD US Operations, LLC5$93
Amneal Pharmaceuticals LLC5$83
Aprecia Pharmaceuticals, LLC5$82
Alnylam Pharmaceuticals Inc.4$80
Impel Pharmaceuticals Inc.4$66
Mallinckrodt Enterprises LLC4$63
Sanofi3$62
Acorda Therapeutics, Inc4$53
Neurocrine Biosciences, Inc.2$51
Azurity Pharmaceuticals, Inc.3$51
Kyowa Kirin, Inc.2$40
Currax Pharmaceuticals LLC3$38
Merz North America, Inc.1$34
Corium, LLC1$32
Sumitomo Pharma America, Inc.1$26
Axsome Therapeutics, Inc.1$24
Neuropace, Inc.1$23
Octapharma USA, Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Kentuckyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$93,107
Medicare patients
314
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$279,195
UbrelvyUbrogepant41$61,031
QuliptaAtogepant25$44,284
Nurtec OdtRimegepant Sulfate28$40,037
Aimovig AutoinjectorErenumab-Aooe17$26,641
RytaryCarbidopa/Levodopa16$18,350
Pyridostigmine Bromide ErPyridostigmine Bromide20$11,191
Levetiracetam132$10,192
Droxidopa14$8,700
Sumatriptan Succinate173$7,638
Lacosamide38$4,847
Pyridostigmine Bromide40$4,486
Memantine Hcl155$4,298
Rivastigmine12$3,638
Primidone41$3,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$319$279,19513 claims
AbbVieUbrelvy, Qulipta$105,064$105,31566 claims
PfizerNurtec Odt$580$40,03728 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$83$22,83756 claims
Upsher-smith Laboratories LLCTopiramate$237$1,829116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Kentuckyon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →